Covid-19 JN.1: Is your vaccine effective against the new variant?

Posted on:
Key Points

While there's ongoing research on vaccine effectiveness against JN.1, experts reveal that booster doses could enhance protection with a better immune response...

Detected in a 79-year-old woman from Karakulam, Thiruvananthapuram district on December 8, 2023, this variant is a descendant of Omicron and closely related to BA.2.86, also known as Pirola, which was first identified in Luxembourg...

Given that the JN.1 variant has been highlighted as a variant with a higher ability to evade immunity and transmissibility, it raises the question if vaccines will be effective against it...

Speaking to IndiaToday.In, Dr Shailesh Sahay, Director of Internal Medicine at Max Hospital in Gurgaon, said, "Vaccinations are essential for reducing the effects of Covid-19 variations, including JN.1..

In a statement, the World Health Organisation (WHO) expert Covid-19 vaccine advisory group recommended sticking with the current XBB.1.5 vaccines, since they seem to provide at least some cross-protection...

You might be interested in

Booster doses of index virus-based vaccines still effective against all COVID-19 variants: WHO

16, Apr, 23

The World Health Organisation said booster doses of index virus-based vaccines continue to confer high levels of protection against severe disease and death caused by all SARS-CoV-2 variants, including contemporary Omicron descendent lineages.

Amid Covid surge, Tricity short of vaccine doses

09, Apr, 23

Since April 1, residents of Chandigarh have been unable to receive the Covid-19 vaccine as stock ended by March 31. The local health department has reached out to the Government of India for additional vaccine supplies, but there is currently no information on when the fresh stock will arrive.

Covid-19 JN.1 variant reaches Delhi: 10 ways to safeguard your health

28, Dec, 23

As Covid-19 variant, JN.1 infection reaches Delhi, expert reveals 10 ways to safeguard your health amid ongoing viral evolution | Health

Gennova Biopharma seeks DCGI nod for its Omicron booster

20, Mar, 23

Gennova has developed an Omicron specific vaccine GEMCOVAC-OM which has been assessed for its safety and immunogenicity when administered as a booster in participants who have received two doses of Covishield and Covaxin, the two main Covid-19 vaccines used in the immunisation drive.

Mexico finally develops own Covid-19 vaccine 'Motherland'

04, May, 23

Vaccine uptake in Mexico dropped precipitously in late 2022 and 2023, and Mexico still has millions of doses of the Abdala vaccine it bought from Cuba.